CVRx today said that medtech veteran Martha Shadan has joined its board of directors.
Shadan has more than 30 years of experience in the life sciences industry and has a long track record of success in commercializing medtech innovations in startups and large companies. She is currently the CEO of Miach Orthopedics. She has also held numerous leadership roles at Smith + Nephew, Rotation Medical, Zimmer Biomet, Covidien, Bristol Myers Squibb and Merck Millipore.
In addition to serving on Minneapolis-based CVRx’s board, Shadan is also a board member at AdvaMed, where she also chairs the diversity and inclusion committee and is a founding member of the Leadership Circle for the Women’s Executive Network (WEN). She also serves as a board advisor for several other companies.
“I am honored to serve on the CVRx board,” Shadan said in a news release. “As the developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, CVRx offers a novel therapy that is a significant advancement inpatient cardiovascular health. I look forward to working with the company as it brings this medical innovation to heart failure patients around the world.”
CVRx said in June that it would plan to trade on the Nasdaq under the symbol CVRX. Its Barostim Neo device uses patented technology to send electrical pulses to baroreceptors in the wall of the carotid artery. The treatment is meant to restore balance to the automatic nervous system and improve the symptoms of heart failure.